S&P 500   4,172.39 (-0.79%)
DOW   32,815.91 (-0.69%)
QQQ   346.94 (-0.87%)
AAPL   178.69 (+0.78%)
MSFT   328.66 (-0.77%)
META   261.64 (-0.34%)
GOOGL   123.10 (-0.46%)
AMZN   119.21 (-2.01%)
TSLA   196.42 (-2.36%)
NVDA   382.33 (-4.68%)
NIO   7.33 (-1.08%)
BABA   78.21 (-0.58%)
AMD   119.01 (-5.00%)
T   15.82 (+1.15%)
F   12.02 (-4.53%)
MU   68.46 (-4.51%)
CGC   0.81 (-4.94%)
GE   100.41 (-1.94%)
DIS   87.36 (-0.52%)
AMC   4.42 (-4.54%)
PFE   37.66 (+1.76%)
PYPL   61.36 (-1.11%)
NFLX   391.88 (-0.28%)
S&P 500   4,172.39 (-0.79%)
DOW   32,815.91 (-0.69%)
QQQ   346.94 (-0.87%)
AAPL   178.69 (+0.78%)
MSFT   328.66 (-0.77%)
META   261.64 (-0.34%)
GOOGL   123.10 (-0.46%)
AMZN   119.21 (-2.01%)
TSLA   196.42 (-2.36%)
NVDA   382.33 (-4.68%)
NIO   7.33 (-1.08%)
BABA   78.21 (-0.58%)
AMD   119.01 (-5.00%)
T   15.82 (+1.15%)
F   12.02 (-4.53%)
MU   68.46 (-4.51%)
CGC   0.81 (-4.94%)
GE   100.41 (-1.94%)
DIS   87.36 (-0.52%)
AMC   4.42 (-4.54%)
PFE   37.66 (+1.76%)
PYPL   61.36 (-1.11%)
NFLX   391.88 (-0.28%)
S&P 500   4,172.39 (-0.79%)
DOW   32,815.91 (-0.69%)
QQQ   346.94 (-0.87%)
AAPL   178.69 (+0.78%)
MSFT   328.66 (-0.77%)
META   261.64 (-0.34%)
GOOGL   123.10 (-0.46%)
AMZN   119.21 (-2.01%)
TSLA   196.42 (-2.36%)
NVDA   382.33 (-4.68%)
NIO   7.33 (-1.08%)
BABA   78.21 (-0.58%)
AMD   119.01 (-5.00%)
T   15.82 (+1.15%)
F   12.02 (-4.53%)
MU   68.46 (-4.51%)
CGC   0.81 (-4.94%)
GE   100.41 (-1.94%)
DIS   87.36 (-0.52%)
AMC   4.42 (-4.54%)
PFE   37.66 (+1.76%)
PYPL   61.36 (-1.11%)
NFLX   391.88 (-0.28%)
S&P 500   4,172.39 (-0.79%)
DOW   32,815.91 (-0.69%)
QQQ   346.94 (-0.87%)
AAPL   178.69 (+0.78%)
MSFT   328.66 (-0.77%)
META   261.64 (-0.34%)
GOOGL   123.10 (-0.46%)
AMZN   119.21 (-2.01%)
TSLA   196.42 (-2.36%)
NVDA   382.33 (-4.68%)
NIO   7.33 (-1.08%)
BABA   78.21 (-0.58%)
AMD   119.01 (-5.00%)
T   15.82 (+1.15%)
F   12.02 (-4.53%)
MU   68.46 (-4.51%)
CGC   0.81 (-4.94%)
GE   100.41 (-1.94%)
DIS   87.36 (-0.52%)
AMC   4.42 (-4.54%)
PFE   37.66 (+1.76%)
PYPL   61.36 (-1.11%)
NFLX   391.88 (-0.28%)

IVERIC bio (ISEE) Stock Forecast, Price & News

$37.75
+0.03 (+0.08%)
(As of 12:34 PM ET)
Compare
Today's Range
$37.46
$37.86
50-Day Range
$22.64
$38.05
52-Week Range
$8.85
$38.25
Volume
1.04 million shs
Average Volume
3.17 million shs
Market Capitalization
$5.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.45

IVERIC bio MarketRank™ Forecast

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
27.1% Downside
$27.45 Price Target
Short Interest
Bearish
8.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of IVERIC bio in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$6.75 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.76) to ($1.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars

Medical Sector

955th out of 1,006 stocks

Pharmaceutical Preparations Industry

472nd out of 492 stocks


ISEE stock logo

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

IVERIC bio, Inc. (NASDAQ:ISEE) Short Interest Update
Iveric bio, Still A 5+% Opportunity
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
IVERIC bio (NASDAQ:ISEE) Coverage Initiated at StockNews.com
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
IVERIC Bio (NASDAQ: ISEE)
IVERIC bio (NASDAQ:ISEE) Downgraded by Stifel Nicolaus
Wedbush Downgrades IVERIC bio (NASDAQ:ISEE) to Neutral
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings
3/01/2023
Today
5/31/2023
Next Earnings (Estimated)
7/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.45
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
-27.4%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$-185,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.46 per share

Miscellaneous

Free Float
133,787,000
Market Cap
$5.21 billion
Optionable
Optionable
Beta
1.10

Key Executives

  • Glenn P. SblendorioGlenn P. Sblendorio
    Chief Executive Officer & Director
  • Pravin U. DugelPravin U. Dugel
    President & Director
  • Keith WestbyKeith Westby
    Chief Operating Officer & Senior Vice President
  • David F. Carroll
    Chief Financial Officer, Treasurer & Senior VP
  • Evelyn M. Harrison
    Chief Clinical Operations Officer & Senior VP













ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ISEE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISEE, but not buy additional shares or sell existing shares.
View ISEE analyst ratings
or view top-rated stocks.

What is IVERIC bio's stock price forecast for 2023?

11 equities research analysts have issued 12-month price objectives for IVERIC bio's stock. Their ISEE share price forecasts range from $18.00 to $35.00. On average, they expect the company's stock price to reach $27.45 in the next twelve months. This suggests that the stock has a possible downside of 27.4%.
View analysts price targets for ISEE
or view top-rated stocks among Wall Street analysts.

How have ISEE shares performed in 2023?

IVERIC bio's stock was trading at $21.41 at the beginning of the year. Since then, ISEE stock has increased by 76.6% and is now trading at $37.80.
View the best growth stocks for 2023 here
.

Are investors shorting IVERIC bio?

IVERIC bio saw a increase in short interest in May. As of May 15th, there was short interest totaling 11,850,000 shares, an increase of 14.5% from the April 30th total of 10,350,000 shares. Based on an average trading volume of 3,750,000 shares, the short-interest ratio is currently 3.2 days.
View IVERIC bio's Short Interest
.

When is IVERIC bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our ISEE earnings forecast
.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) posted its quarterly earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.10. During the same quarter in the previous year, the business posted ($0.29) EPS.

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.39%), Price T Rowe Associates Inc. MD (4.97%), State Street Corp (4.08%), American Century Companies Inc. (2.95%), Braidwell LP (2.71%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends
.

How do I buy shares of IVERIC bio?

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $37.80.

How much money does IVERIC bio make?

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $5.21 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -